- In patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), surveillance 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) at day +100 after autologous hematopoietic cell transplantation (AHCT), researchers detected asymptomatic relapse in approximately one-third of patients.
- High peak standardized uptake value (SUVmax) at day +100 PET was linked to inferior survival.
Why this matters
- PET/CT has already demonstrated value in identifying patients with DLBCL at high risk for treatment failure before AHCT and in predicting long-term clinical outcomes.
- Study to investigate the value of surveillance 18F-FDG PET/CT at day +100 after AHCT in 91 patients with DLBCL.
- Median age at transplant, 60 (range, 19-73) years.
- All patients received PET/CT at a median of 44 (range, 32-55) days before AHCT.
- Funding: None disclosed.
- 60 relapse/progression events were observed; 35% were detected with day +100 imaging.
- 76% of patients did not experience B symptoms at the time of post-AHCT relapse.
- 4-fold higher risk for overall mortality in patients with post-AHCT Deauville score of 5 vs 1 (HR, 4.10; 95% CI, 1.56-10.77; P≤.01).
- Mortality risk increased with each doubling of SUVmax (HR, 1.7; 95% CI, 1.3-2.3; P≤.01).
- Single-center retrospective analysis.